Article contributed by: Tristan Salomon, founder and CEO of Axom, and expert in Machine Learning, Big Data and AI. Any business needs to possess top-level technological advances not just to stand out from, but at least to keep up with the competition. This is especially true for pharmaceutical companies. The current pandemic situation has tested them on the ability to … [Read more...]
Absci and Merck collaborate to develop new enzymes
As part of the collaboration, the company will use its Deep Learning-Enabled Drug Creation and Bionic Protein non-standard amino acid technologies to create enzymes to meet Merck’s biomanufacturing The post Absci and Merck collaborate to develop new enzymes appeared first on Pharmaceutical Business review. … [Read more...]
US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment
The latest move follows the receipt of European Commission (EC) approval for the drug in December last year. Cibinqo, the oral small molecule drug, selectively hinders Janus kinase The post US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment appeared first on Pharmaceutical Business review. … [Read more...]
Pfizer, Beam sign multi-target research collaboration for rare diseases
The collaboration will see the base editing programmes to be evaluated leverage Beam’s in vivo delivery technologies. These technologies use messenger RNA (mRNA) and lipid nanoparticles (LNP) to The post Pfizer, Beam sign multi-target research collaboration for rare diseases appeared first on Pharmaceutical Business review. … [Read more...]
AbbVie seeks approval for upadacitinib to treat nr-axSpA
A selective JAK inhibitor, Rinvoq is currently being analysed in various immune-mediated inflammatory diseases. Both the submissions are supported by the Phase III SELECT-AXIS 2 (Study 2) clinical The post AbbVie seeks approval for upadacitinib to treat nr-axSpA appeared first on Pharmaceutical Business review. … [Read more...]